Latest Content

New bipartisan legislation would ban parent companies from owning insurers or PBMs and providers or management services organizations simultaneously.

Margaret Krackeler, MD, of Kaiser Permanente Northern California, shares lessons on implementing evidence-based formulary changes for patients with CLL.

This study evaluates inclusion of National Comprehensive Cancer Network (NCCN) guideline recommended biomarkers for metastatic non–small cell lung cancer (NSCLC) in commercially available targeted next-generation sequencing (NGS) panels.

As pharmaceutical R&D policies evolve, the authors argue it is crucial to embed American patient values in reimbursement deliberations and frameworks.

OCEANIC-STROKE trial data show asundexian cuts ischemic stroke across subtypes with no rise in major bleeding, which could reshape antithrombotic choices.

Many older HFpEF patients appear to have CKD from aging and obesity; visceral adiposity drives kidney risk more than intrinsic damage or low eGFR.

Meaningful reductions in all-cause mortality and cardiovascular hospitalizations modeled benefits compared with untreated populations.

A stronger effect on neovascular age-related macular degeneration (nAMD) was found with faricimab vs aflibercept.

Andrew Yee, MD, explains how academic centers can share practical oncology best practices that community hospitals can implement sustainably.